Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLAST MRD AML-2
NCT04284787Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2021
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Feb 2021; status: active, not recruiting.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04284787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04284787.